Mounjaro for teenagers with obesity (Credits: iStock) Weight-loss injections have become a major talking point in obesity treatment, but could they also help teenagers struggling with excess weight? A new clinical trial published in JAMA has found that tirzepatide, the drug sold under brand names such as Mounjaro, significantly reduced body mass index (BMI) in adolescents living with obesity. The Phase 3 SURMOUNT-ADOLESCENTS trial, published online on November 15, 2026, investigated the effects of once-weekly tirzepatide in 160 adolescents aged 12 to under 18 years. The findings showed that participants receiving the medication experienced an average 18.5% reduction in BMI over 72 weeks, compared with a 0.5% increase among those given a placebo. The study involved adolescents with obesity or those who were overweight and had at least one obesity-related health complication. Participants were divided into two groups, with 109 receiving tirzepatide and 51 receiving a placebo. Both groups also received lifestyle support, including guidance on healthy eating and increased physical activity. The results were particularly significant when researchers examined how many participants achieved different levels of BMI reduction. Around 79.6% of adolescents receiving tirzepatide recorded at least a 5% reduction in BMI. Meanwhile, 71.4% achieved a reduction of at least 10%, while 48.1% experienced a reduction of 20% or more. Importantly, approximately 54% of participants receiving tirzepatide no longer met the clinical BMI threshold for obesity by the end of the 72-week trial. Tirzepatide works by activating two hormone receptors, GIP and GLP-1, which are involved in regulating appetite, food intake and blood sugar levels. By influencing these pathways, the medication can reduce hunger, increase feelings of fullness and help people consume fewer calories. However, an 18.5% reduction in BMI should not be confused with an 18.5% reduction in body weight. These are two different measurements. Also, the medication was not without side effects. Gastrointestinal problems were the most frequently reported adverse events, with vomiting, nausea and diarrhoea among the common complaints. Most were mild to moderate in severity and occurred more frequently during the dose-escalation period. While the findings offer promising evidence that medications such as tirzepatide could become an important part of adolescent obesity treatment, researchers will need to understand how sustainable these results are over a longer period. Obesity is a chronic condition, and managing it often requires continued medical support rather than a short-term weight-loss intervention. There are also important questions about what happens when teenagers stop taking the medication, whether the weight loss can be maintained and what the long-term effects could be on their growth, development and overall health. Since adolescence is a critical period of physical and hormonal development, prescribing weight-loss medication requires a particularly careful approach. The findings do not mean that every teenager struggling with excess weight should be considered for weight-loss injections. Treatment decisions must account for an individual's health, medical history and obesity-related complications. For now, the study adds to growing evidence that obesity treatment may need to go beyond lifestyle changes alone, while reinforcing the importance of medical supervision, nutritional guidance and long-term care. Simran covers books that start conversations, beauty insights, fashion moods, and stories that make people feel something. Off duty? You’ll find her c... View More